Olaratumab

Lartruvo

190 MG / 19 ML SolutionCanadaCancelledAuthorised 9 Jun 2020

Open in the registerAsk Osler about it

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Olaratumab

Lartruvo

190 MG / 19 ML SolutionCanadaCancelledAuthorised 9 Jun 2020

Open in the registerAsk Osler about it

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Register entryHealth Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Olaratumab
Strength: 190 MG / 19 ML
Dosage form: Solution
Route: Intravenous
Register: Canada (Health Canada)
Status: Cancelled
Status in the register: Cancelled Post Market
Authorised: 9 Jun 2020
Registration: DIN 02480271
Marketing authorisation holder: Eli Lilly Canada INC
ATC code: L01FX10
Group: Antineoplastic and immunomodulating agents
Supply: PRESCRIPTION, SCHEDULE D